Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 141
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05461690 | Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency | ||
| NCT06327698 | Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure | ||
| NCT07098026 | Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer | ||
| NCT02527057 | Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer | ||
| NCT03880695 | Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma | ||
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | ||
| NCT05907447 | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types | ||
| NCT03351062 | Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer | ||
| NCT07163481 | A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | ||
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | ||
| NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | ||
| NCT05273944 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients | ||
| NCT05211232 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | ||
| NCT05042908 | Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies | ||
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | ||
| NCT06748495 | Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer | ||
| NCT06328439 | A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors | ||
| NCT07005999 | Interventional Ablation for Early-stage Lung Cancer | ||
| NCT05633914 | Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer | ||
| NCT02355249 | Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer | ||
| NCT01616849 | Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma | ||
| NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | ||
| NCT04922450 | Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | ||
| NCT02448966 | Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy | ||
| NCT06734533 | Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) . | ||
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | ||
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | ||
| NCT04823468 | Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma | ||
| NCT05351346 | Genotype-guided Treatment in DLBCL | ||
| NCT07459296 | Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC | ||
| NCT07237828 | Drain Removal on Postoperative Safety and Patient Satisfaction in R-E-NSM With Prepectoral DIBR | ||
| NCT06440954 | Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | ||
| NCT05244499 | Evidence-based Leadership in Nurse Leaders-CH | ||
| NCT06350838 | Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC) | ||
| NCT06752798 | Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC | ||
| NCT07083687 | Lorlatinib in ROS1+ NSCLC With Brain Metastasis | ||
| NCT06011330 | Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer | ||
| NCT05980208 | A Real-world Study of Inetetamab for First-line Treatment of MBC | ||
| NCT03066310 | Urine-DNA Biomarkers in Detecting Bladder Cancer | ||
| NCT05955391 | TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) | ||
| NCT03895788 | A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | ||
| NCT03286920 | Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer | ||
| NCT05872880 | TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. | ||
| NCT04974827 | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer | ||
| NCT02395705 | Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma | ||
| NCT06992687 | A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors | ||
| NCT05356351 | An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer | ||
| NCT03146455 | Thromboelastography Normal Reference Values in China Hunan Province | ||
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | ||
| NCT06682884 | Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer |
